Rimonabant in abdominal obesity with impaired fasting glucose

Phase 4, randomised, double-blind trial in Abdominal adiposity (ABCD) and impaired fasting glucose (IFG) comparing Rimonabant with Placebo (2 arms). Primary endpoints: Mean change from baseline to month 12 in fasting plasma glucose, Mean change from baseline to month 12 in HDL-cholesterol and 1 more. Started Jul 2006; status: terminated.